Brand name · Radium ra 223 dichloride
Xofigo: adverse event reports filed with FDA
4,667 reports list it as a suspect or interacting product, 2013–2026.
- 4,667
- reports as suspect product
- 0% of all reports · about 357 a year
- 143
- reports, 12 months to June 2026
- 218 in the 12 months before
- 89.4%
- marked serious by the reporter
- 57.4% across all reports
- 20.2%
- record death among outcomes, as reported
- 941 reports · not verified by FDA
Between June 2013 and June 2026, 4,667 adverse event reports received by FDA list the brand name Xofigo (radium ra 223 dichloride) as a suspect or interacting product. Reports that mention it only as a concomitant medication (232) are left out of every figure here.
In the 12 months to June 2026, 143 reports listed it, down 34% from 218 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 357 reports a year and 0% of the 20,646,523 reports in the database. How many people take it is not in the data, so a count is not a rate of occurrence.
Reporters most often recorded prostatic specific antigen increased (9.4%), hormone-refractory prostate cancer (9.3%) and death (8.4%). A report can list several reactions, so shares add to more than 100%; 439 different terms appear across these reports. Prostatic specific antigen increased is recorded in 9.4% of these reports, against 0.1% of all reports in the database.
89.4% of the reports are marked serious by the reporter; 20.2% record death among the outcomes and 23.1% record hospitalisation, as reported. 53.4% of the reports came from physicians, and the largest patient age group is 75 and over (23.7%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Xofigo reports recording the termall reports in the database
- Hormone-refractory prostate cancer9.3%433
- Deaththe patient died; cause not stated by this term8.4%394
- Metastases to bone6.8%316
- General physical health deteriorationgeneral decline in health6.5%304
- Anaemialow red blood cells5.6%262
- Haemoglobin decreasedlow haemoglobin5.1%239
- Disease progressionthe disease advanced4.6%215
- Painpain, site not specified4.6%213
- Nauseafeeling sick4.5%212
- Prostate cancer4.4%206
- Fatiguetiredness4.2%198
- Malaisegeneral feeling of being unwell4.2%197
- Diarrhoealoose or frequent stools4%186
- Platelet count decreasedlow platelet count3.9%184
- Metastases to liver3.7%174
- Astheniaweakness or lack of energy3.7%171
- Decreased appetitereduced appetite3.2%148
- Bone painbone pain2.8%130
- Thrombocytopenialow platelets2.5%119
- Prostate cancer metastatic2.5%115
- Pancytopenialow counts of all blood cells2.4%112
- Vomitingbeing sick2.2%104
- Hospitalisationadmission to hospital2%94
- Back painback pain2%93
- Falla fall1.8%86
- Pneumonialung infection1.8%83
- Laboratory test abnormal1.8%82
- Weight decreasedweight loss1.8%82
Top 30 of 439 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the share of all reports in the database; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 20,646,523 reports. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 33.1% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Hormone-refractory prostate cancer | 1,251 | 26.8% |
| Metastases to bone | 525 | 11.2% |
| Prostate cancer | 469 | 10% |
| Prostate cancer metastatic | 340 | 7.3% |
| Prostate cancer stage iv | 208 | 4.5% |
| Metastasis | 12 | 0.3% |
The indication field is filled in by the reporter and is often blank; shares are of all 4,667 reports.
Drugs most often listed in the same reports
| Drug (any role in the report) | Reports | Share of Xofigo reports |
|---|---|---|
| Xtandi | 168 | 3.6% |
| Xgeva | 127 | 2.7% |
| Zytiga | 119 | 2.5% |
| Enzalutamide | 116 | 2.5% |
| Denosumab | 101 | 2.2% |
| Docetaxel | 88 | 1.9% |
| Prednisone | 69 | 1.5% |
| Abiraterone | 68 | 1.5% |
| Lupron | 66 | 1.4% |
| Cabazitaxel | 57 | 1.2% |
Other products listed in reports where Xofigo is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.
In context
| Measure | Xofigo | All reports |
|---|---|---|
| Reports as suspect product | 4,667 | 20,646,523 |
| Share of that pool | — | 0% |
| Reports, latest 12 months | 143 | 1,332,454 |
| Marked serious | 89.4% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 202 | 91 |
| Hospitalisation recorded, per 1,000 reports | 231 | 213 |
| Consumer-filed share | 22.9% | 45.8% |
| Top term, share of reports | Prostatic specific antigen increased 9.4% | 0.1% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Questions about Xofigo reports
How many adverse event reports has FDA received for Xofigo?
4,667 reports list Xofigo as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 143 of them arrived in the latest 12 months. Another 232 list it only as a concomitant medication.
What reactions are recorded in Xofigo reports?
prostatic specific antigen increased (9.4%), hormone-refractory prostate cancer (9.3%), death (8.4%), metastases to bone (6.8%) and general physical health deterioration (6.5%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Xofigo was responsible.
How serious are the reports?
89.4% are marked serious by the reporter. Among the outcomes recorded, 20.2% of reports include death and 23.1% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
physician (53.4%), consumer or non-health professional (22.9%) and other health professional (22.2%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Xofigo rising?
143 reports in the 12 months to June 2026, down 34% from 218 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Xofigo was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Xofigo?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Xofigo as a suspect or interacting product; reports listing it only as a concomitant medication (232) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.